TY - JOUR
T1 - Clinical Significance of Extracellular Vesicles in Prostate and Renal Cancer
AU - Chen, Tzu Yi
AU - Mihalopoulos, Meredith
AU - Zuluaga, Laura
AU - Rich, Jordan
AU - Ganta, Teja
AU - Mehrazin, Reza
AU - Tsao, Che Kai
AU - Tewari, Ash
AU - Gonzalez-Kozlova, Edgar
AU - Badani, Ketan
AU - Dogra, Navneet
AU - Kyprianou, Natasha
N1 - Publisher Copyright:
© 2023 by the authors.
PY - 2023/10
Y1 - 2023/10
N2 - Extracellular vesicles (EVs)—including apoptotic bodies, microvesicles, and exosomes—are released by almost all cell types and contain molecular footprints from their cell of origin, including lipids, proteins, metabolites, RNA, and DNA. They have been successfully isolated from blood, urine, semen, and other body fluids. In this review, we discuss the current understanding of the predictive value of EVs in prostate and renal cancer. We also describe the findings supporting the use of EVs from liquid biopsies in stratifying high-risk prostate/kidney cancer and advanced disease, such as castration-resistant (CRPC) and neuroendocrine prostate cancer (NEPC) as well as metastatic renal cell carcinoma (RCC). Assays based on EVs isolated from urine and blood have the potential to serve as highly sensitive diagnostic studies as well as predictive measures of tumor recurrence in patients with prostate and renal cancers. Overall, we discuss the biogenesis, isolation, liquid-biopsy, and therapeutic applications of EVs in CRPC, NEPC, and RCC.
AB - Extracellular vesicles (EVs)—including apoptotic bodies, microvesicles, and exosomes—are released by almost all cell types and contain molecular footprints from their cell of origin, including lipids, proteins, metabolites, RNA, and DNA. They have been successfully isolated from blood, urine, semen, and other body fluids. In this review, we discuss the current understanding of the predictive value of EVs in prostate and renal cancer. We also describe the findings supporting the use of EVs from liquid biopsies in stratifying high-risk prostate/kidney cancer and advanced disease, such as castration-resistant (CRPC) and neuroendocrine prostate cancer (NEPC) as well as metastatic renal cell carcinoma (RCC). Assays based on EVs isolated from urine and blood have the potential to serve as highly sensitive diagnostic studies as well as predictive measures of tumor recurrence in patients with prostate and renal cancers. Overall, we discuss the biogenesis, isolation, liquid-biopsy, and therapeutic applications of EVs in CRPC, NEPC, and RCC.
KW - exosomes
KW - liquid biopsies
KW - prediction
KW - therapeutic targeting
KW - tumor progression
UR - http://www.scopus.com/inward/record.url?scp=85174698612&partnerID=8YFLogxK
U2 - 10.3390/ijms241914713
DO - 10.3390/ijms241914713
M3 - Review article
C2 - 37834162
AN - SCOPUS:85174698612
SN - 1661-6596
VL - 24
JO - International Journal of Molecular Sciences
JF - International Journal of Molecular Sciences
IS - 19
M1 - 14713
ER -